Stereoselective targeting with chiral nanomaterials: A strategy for precision therapy in neurodegenerative diseases
Source abstract
Abstract
The challenge in treating neurodegenerative diseases (NDs) lies in the complexity of their pathological mechanisms. Strategies capable of synergistically regulating multiple pathological features are crucial for treating NDs. Chiral nanomaterials (CNMs), including chiral nanoparticles (CNPs) and chiral nanoassemblies (CAMs), offer a unique platform for achieving such precise multitarget regulation because of their stereoselective interactions. Strategies for synthesizing CNMs are outlined in this review, and an in-depth analysis of their core biological mechanisms for treating NDs-inhibiting and clearing pathological proteins, enhancing synaptic plasticity, alleviating neuroinflammation, selectively eliminating senescent cells and promoting the differentiation of neural stem cells-is provided. Optimization of these functions through internal chiral design and external physical field modulation is explored. Finally, we propose forward-looking concepts such as "stage-optimized chiral nanomedicines" and "intelligently responsive chiral nanomaterials" to provide guidance for next-generation precision nanomedicine for NDs. STATEMENT OF SIGNIFICANCE: The key challenge in treating neurodegenerative diseases (NDs) lies in the precise identification and coordinated regulation of multi-target pathological processes. In recent years, chiral nanomaterials (CNMs), including chiral nanoparticles (CNPs) and chiral nanoassemblies (CAMs), have emerged as innovative tools for NDs intervention owing to their unique stereoselective recognition capabilities. This review systematically categorizes CNMs and their synthesis strategies, and focuses on elucidating their core biological mechanisms, including the inhibition and clearance of pathological proteins, enhancement of synaptic plasticity, alleviation of neuroinflammation, selective elimination of senescent cells, and promotion of neural stem cell differentiation. Furthermore, strategies to optimize their functionality through internal chiral structure design and external physical field modulation are explored. Collectively, this review aims to systematically elucidate the biological mechanisms and material properties of CNMs in NDs therapy, providing a theoretical foundation and guidance for the rational design and construction of next-generation neurorepair materials.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Supramolecular Self-Assembly in Materials · Polydiacetylene-based materials and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Neurodegenerative diseases10.1038/539179a ↗
2. Ageing, neurodegeneration and brain rejuvenation10.1038/nature20411 ↗
3. Neurodegenerative disorders-searching for targets and new ways of diseases treatment10.1002/med.21794 ↗
4. Pathology of neurodegenerative diseases10.1101/cshperspect.a028035 ↗
5. Hallmarks of neurodegenerative diseases10.1016/j.cell.2022.12.032 ↗
6. Mechanical design and multifunctional applications of chiral mechanical metamaterials: a review10.1016/j.matdes.2019.107950 ↗
7. Molecular to organismal chirality is induced by the conserved myosin 1D
8. On the origins of life's homochirality: inducing enantiomeric excess with spin-polarized electrons10.1073/pnas.2204765119 ↗
9. The origin of biological homochirality10.1101/cshperspect.a032540 ↗
10. Enantioselective recognition of an isomeric ligand by a biomolecule: mechanistic insights into static and dynamic enantiomeric behavior and structural flexibility10.1039/C7MB00378A ↗
11. Self-assembled inorganic chiral superstructures10.1038/s41570-021-00350-w ↗
12. Chiral inorganic nanostructures10.1021/acs.chemrev.6b00755 ↗
13. Cell chirality as a novel measure for cytotoxicity
14. Chiral biointerface materials10.1039/C1CS15209B ↗
15. A self-destructive nanosweeper that captures and clears amyloid β-peptides10.1038/s41467-018-04255-z ↗
16. Cysteine-derived chiral carbon quantum dots: a fibrinolytic activity regulator for Plasmin to target the Human islet amyloid polypeptide for type 2 diabetes mellitus10.1021/acsami.2c17975 ↗
17. Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer's Disease mice10.1021/acs.nanolett.8b03644 ↗
18. Chiral effect on aβ fibrillation from molecular-scale to nanoscale10.1007/s12274-022-4303-9 ↗
19. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer's disease10.1038/s41467-020-18525-2 ↗
20. Chiral Cu(x)Co(y)S-Cu(z)S nanoflowers with bioinspired enantioselective catalytic performances10.1002/smll.202311275 ↗
21. Stereoselective nanozyme based on ceria nanoparticles engineered with amino acids
22. Electromagnetic field-enhanced chiral dimanganese trioxide nanoparticles mitigate Parkinson’s disease10.1007/s11426-022-1321-0 ↗
23. Neurodegenerative disorders: mechanisms of degeneration and therapeutic approaches with their clinical relevance10.1016/j.arr.2024.102357 ↗
24. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases10.1038/s41568-019-0205-x ↗
25. Reevaluating the substrate specificity of the l-type amino acid transporter (LAT1)10.1021/acs.jmedchem.8b01007 ↗
26. Functionalized nanomaterials capable of crossing the blood-brain barrier10.1021/acsnano.3c10674 ↗
27. Light-controlled self-assembly of semiconductor nanoparticles into twisted ribbons
28. Bioinspired chiral nanozymes: synthesis strategies, classification, biological effects and biomedical applications10.1016/j.ccr.2023.215601 ↗
29. Chiral modulation of amyloid beta fibrillation and cytotoxicity by enantiomeric carbon dots10.1039/C8CC03235A ↗
30. Chiral molecule-mediated porous Cu (x) O nanoparticle clusters with antioxidation activity for ameliorating Parkinson's Disease10.1021/jacs.8b11856 ↗
31. Adenine oligomer directed synthesis of chiral gold nanoparticles10.1038/s41467-022-31513-y ↗
32. Intrinsic chirality of CdSe/ZnS quantum dots and quantum rods10.1021/nl504439w ↗
33. Machine learning for nanoplasmonics10.1038/s41565-022-01284-0 ↗
34. New benchmark in DNA-based asymmetric catalysis: prevalence of modified DNA/RNA hybrid systems10.1021/jacsau.2c00271 ↗
35. Chiral effect at protein/graphene interface: a bioinspired perspective to understand amyloid formation10.1021/ja5049626 ↗
36. Cell chirality: its origin and roles in left-right asymmetric development
37. Aβ1-6A2V(D) peptide, effective on aβ aggregation, inhibits tau misfolding and protects the brain after traumatic brain injury10.1038/s41380-023-02101-3 ↗
38. d-amino acid-containing supramolecular nanofibers for potential cancer therapeutics10.1016/j.addr.2016.04.008 ↗
39. Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice10.1016/j.biomaterials.2015.11.060 ↗
40. Chiral effect at Nano-bio interface: a model of Chiral gold nanoparticle on amylin fibrillation10.3390/nano9030412 ↗
41. Enantiomers of cysteine-modified SeNPs (d/lSeNPs) as inhibitors of metal-induced aβ aggregation in Alzheimer's disease10.1039/C5TB00731C ↗
42. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins
43. Anti-PEG antibodies enriched in the protein corona of PEGylated nanocarriers impact the cell uptake10.1039/D3NH00198A ↗
44. Stability of lipid coatings on nanoparticle-decorated surfaces10.1021/acsnano.0c07298 ↗
45. Modulation of nano-superstructures and their optical properties10.1021/acs.accounts.2c00202 ↗
46. Supramolecular chirality in self-assembled systems10.1021/cr500671p ↗
47. Stereospecific supramolecular polymerization of nanoclusters into ultra-long helical chains and enantiomer separation10.1038/s41467-024-52402-6 ↗
48. Hierarchical self-assembly into chiral nanostructures10.1039/D1SC03561D ↗
49. Chiroptical switching and strong circularly polarized luminescence in peptide supramolecular assemblies10.1038/s41467-025-61007-6 ↗
50. Supramolecular chirality transfer toward chiral aggregation: asymmetric hierarchical self-assembly
51. Engineering DNA self-assemblies as templates for functional nanostructures10.1021/ar400305g ↗
52. Chiral template-directed regio-, diastereo-, and enantioselective photodimerization of an anthracene derivative assisted by complementary amidinium-carboxylate Salt Bridge formation10.1021/jacs.7b03317 ↗
53. Chiral MoS(2)@BC fibrous membranes selectively promote peripheral nerve regeneration10.1186/s12951-024-02493-6 ↗
54. Chiral metallohelical complexes enantioselectively target amyloid β for treating Alzheimer's disease10.1021/ja502789e ↗
55. Chiral skeletons of mesoporous silica nanospheres to mitigate Alzheimer's β-amyloid aggregation10.1021/jacs.2c12214 ↗
56. Detection of amyloid fibrils in Parkinson's disease using plasmonic chirality10.1073/pnas.1721690115 ↗
57. Stimulation of neural stem cell differentiation by circularly polarized light transduced by chiral nanoassemblies10.1038/s41551-020-00634-4 ↗
58. Self-assembled chiral phosphorescent microflowers from Au nanoclusters with dual-mode pH sensing and information encryption10.1021/acsnano.0c09766 ↗
59. Self-assembled chiral nanoparticle superstructures and identification of their collective optical activity from Ligand asymmetry10.1021/acsnano.8b06269 ↗
60. Self-assembly of chiral nanoparticles into semiconductor helices with tunable near-infrared optical activity10.1021/acs.chemmater.9b04143 ↗
61. Transmission of chirality through space and across length scales10.1038/nnano.2017.62 ↗
62. Chiral templating of self-assembling nanostructures by circularly polarized light10.1038/nmat4125 ↗
63. Reconfigurable homochiral colloidal clusters assembled under orthogonally applied electric and magnetic fields10.1073/pnas.2418006122 ↗
64. Nanoscale forces and their uses in self-assembly10.1002/smll.200900358 ↗
65. Structural colour printing using a magnetically tunable and lithographically fixable photonic crystal10.1038/nphoton.2009.141 ↗
66. Helical magnetic field-induced real-time plasmonic chirality modulation10.1021/acsnano.0c02026 ↗
67. Selection of supramolecular chirality by application of rotational and magnetic forces10.1038/nchem.1264 ↗
68. Vortexes tune the chirality of graphene oxide and its non-covalent hosts10.1039/C6CC05177D ↗
69. Reconfigurable metasurfaces that enable light polarization control by light10.1038/lsa.2016.254 ↗
70. Maxwell lattices and topological mechanics10.1146/annurev-conmatphys-033117-054235 ↗
71. The amyloid hypothesis of Alzheimer's disease at 25 years10.15252/emmm.201606210 ↗
72. Alzheimer's disease10.1111/ene.13439 ↗
73. Alzheimer's disease: the amyloid cascade hypothesis
74. Hypothesis: tau pathology is an initiating factor in sporadic Alzheimer's disease10.1002/alz.12192 ↗
75. Targeting synapse function and loss for treatment of neurodegenerative diseases10.1038/s41573-023-00823-1 ↗
76. Anti-amyloid therapies for Alzheimer's Disease and the Amyloid cascade hypothesis10.3390/ijms241914499 ↗
77. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)10.1016/0896-6273(94)90458-8 ↗
78. Truncated and modified amyloid-beta species10.1186/alzrt258 ↗
79. Diversity of amyloid-beta proteoforms in the Alzheimer's Disease brain10.1038/s41598-017-10422-x ↗
80. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β10.1038/nature11060 ↗
81. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta10.1021/bi990563r ↗
82. Alpha-helix targeting reduces amyloid-beta peptide toxicity10.1073/pnas.0810364106 ↗
83. A focused chiral mutant library of the amyloid β 42 Central electrostatic cluster as a tool to stabilize aggregation intermediates10.1021/acs.joc.9b02312 ↗
84. Antimicrobial α-defensins as multi-target inhibitors against amyloid formation and microbial infection10.1039/D1SC01133B ↗
85. Direct observation of the interconversion of normal and toxic forms of α-synuclein10.1016/j.cell.2012.03.037 ↗
86. Molecular chirality mediated amyloid formation on phospholipid surfaces10.1039/D0SC02212H ↗
87. The cucurbit[7]uril-based supramolecular chemistry for reversible B/Z-DNA transition
88. Effect of chirality on cell spreading and differentiation: from chiral molecules to chiral self-assembly10.1021/acsami.9b15710 ↗
89. Cell chirality drives left-right asymmetric morphogenesis10.3389/fcell.2018.00034 ↗
90. Inhibition of GSK3β by pharmacological modulation of sphingolipid metabolism occurs independently of ganglioside disturbance in a cellular model of Alzheimer's disease10.1016/j.expneurol.2015.06.021 ↗
91. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
92. Molecular dynamics simulations of copper binding to N-terminus mutants of amyloid-β10.1080/07391102.2020.1745692 ↗
93. In vivo conversion of racemized β-amyloid ([D-Ser26]Aβ1–40) to truncated and toxic fragments ([D-Ser26]Aβ25–35/40) and fragment presence in the brains of Alzheimer's patients10.1002/jnr.10391 ↗
94. Immobilization of d-allulose 3-epimerase into magnetic metal-organic framework nanoparticles for efficient biocatalysis10.1007/s11274-022-03330-4 ↗
95. Microglial aβ receptors in Alzheimer's disease10.1007/s10571-014-0101-6 ↗
96. Intranasal delivery of pure nanodrug loaded liposomes for Alzheimer's Disease treatment by efficiently regulating microglial polarization10.1002/smll.202405781 ↗
97. Enantiomer-dependent supramolecular immunosuppressive modulation for tissue reconstruction10.1021/acsnano.3c11601 ↗
98. Photosensitizing materials and platforms for light-triggered modulation of Alzheimer's β-amyloid self-assembly10.1016/j.biomaterials.2018.10.043 ↗
99. Carbon nanodot-sensitized modulation of Alzheimer's β-amyloid self-assembly
100. Light-induced chiral iron copper selenide nanoparticles prevent β-amyloidopathy In vivo10.1002/anie.202002028 ↗